1
|
Gosselin RC. From Ink Pens to Computers: A Personal Look Back at Landmark Changes during 5 Decades as a Clinical Laboratory Scientist in U.S. Hemostasis Laboratories. Semin Thromb Hemost 2023; 49:225-233. [PMID: 36174603 DOI: 10.1055/s-0042-1756708] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
In 2023, Seminars in Thrombosis and Hemostasis will be celebrating its 50th anniversary, and similarly this will also mark my 5th decade of working in, or association with, laboratories that perform hemostasis testing. My career started at a large military medical center, but I also worked at several other facilities, including military dispensaries, community hospitals, and a large academic institution. The difference between each type of hemostasis laboratory was as expected, with larger facilities having better instrumentation and more prolific test menus. However, whether one worked in a large academic center, or a small rural hospital, regulatory changes affected every clinical laboratory to the same degree. Advances in technology also eventually affected every hemostasis laboratory, but these salient changes were more likely to occur earlier at the larger institutions. As Seminars in Thrombosis and Hemostasis celebrates its 50th anniversary, that milestone triggered recollection about those salient events that occurred during my own career in hemostasis testing. As such, I describe (my impression) the top ten landmark changes that altered laboratory practice at the facilities where I worked during the past 5 decades.
Collapse
Affiliation(s)
- Robert C Gosselin
- Thrombosis and Hemostasis Center University of California, Davis Health System, Sacramento, California
| |
Collapse
|
2
|
Bitan J, Bajolle F, Harroche A, Cannet P, Braems A, Taleb S, Bonnet D, Borgel D, Lasne D. A retrospective analysis of discordances between international normalized ratio (INR) self-testing and INR laboratory testing in a pediatric patient population. Int J Lab Hematol 2021; 43:1575-1584. [PMID: 34237187 DOI: 10.1111/ijlh.13652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 05/29/2021] [Accepted: 06/21/2021] [Indexed: 11/29/2022]
Abstract
INTRODUCTION The lack of quality control procedures for home point-of-care (POC) international normalized ratio (INR) devices is a concern. Concomitant laboratory and POC INR testing may be proposed to overcome the lack of quality control. However, a difference between the POC INR and the laboratory INR is not necessarily due to failure of the POC device. This study aimed to identify variables associated with a significant deviation between the POC INR and the laboratory INR. METHODS Children included in this retrospective cohort study performed at least one concomitant laboratory and POC INRs. Clinical and laboratory variables were assessed for an association with significant deviation within pairs of INR. RESULTS A significant deviation was noted for 30 (15.3%) of the 196 pairs of INR measurements from 124 children. Relative to patients without deviations, patients with deviations were younger (odds ratio =0.91; P = .020), less experienced in the use of POC INR devices (odds ratio =0.89; P = .098), and more likely to have received an INR result from a laboratory using animal thromboplastin (odds ratio =2.81 vs. 0.37 for laboratories using human thromboplastin; P = .016). In a multivariate analysis, younger age and the laboratory's use of animal thromboplastin were associated with significant deviations. CONCLUSIONS Although most children had coherent pairs of INR values, the occurrence of deviations raises the question of the origin of the thromboplastin used in the laboratory and emphasizes the need to provide specific quality control procedures for POC INR devices.
Collapse
Affiliation(s)
- Joan Bitan
- Hematology Laboratory, Hôpital universitaire Necker-Enfants Malades, AP-HP, Paris, France
| | - Fanny Bajolle
- M3C-Necker, Cardiologie Congénitale et Pédiatrique, Hôpital universitaire Necker-Enfants Malades, AP-HP, Paris, France.,Universite de Paris, Paris, France
| | - Annie Harroche
- Centre de Traitement de l'Hémophilie, Hôpital universitaire Necker-Enfants Malades, AP-HP, Paris, France
| | - Pauline Cannet
- M3C-Necker, Cardiologie Congénitale et Pédiatrique, Hôpital universitaire Necker-Enfants Malades, AP-HP, Paris, France
| | - Alice Braems
- M3C-Necker, Cardiologie Congénitale et Pédiatrique, Hôpital universitaire Necker-Enfants Malades, AP-HP, Paris, France
| | - Sofiane Taleb
- Hematology Laboratory, Hôpital universitaire Necker-Enfants Malades, AP-HP, Paris, France
| | - Damien Bonnet
- M3C-Necker, Cardiologie Congénitale et Pédiatrique, Hôpital universitaire Necker-Enfants Malades, AP-HP, Paris, France.,Universite de Paris, Paris, France
| | - Delphine Borgel
- Hematology Laboratory, Hôpital universitaire Necker-Enfants Malades, AP-HP, Paris, France.,HITh, UMR_S 1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicetre, France
| | - Dominique Lasne
- Hematology Laboratory, Hôpital universitaire Necker-Enfants Malades, AP-HP, Paris, France.,HITh, UMR_S 1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicetre, France
| |
Collapse
|
3
|
Gardiner C, Kohama K, Patel I, Lane P, Dwyer S, Machin SJ, Mackie IJ. A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem™PT). Int J Lab Hematol 2017; 39:532-538. [DOI: 10.1111/ijlh.12691] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 03/30/2017] [Indexed: 11/30/2022]
Affiliation(s)
| | | | - I. Patel
- University College London; London UK
- Sysmex UK; Milton Keynes UK
| | - P. Lane
- University College London; London UK
| | - S. Dwyer
- Sidra Medical and Research Center; Doha Qatar
| | | | | |
Collapse
|
4
|
Biedermann JS, van den Besselaar AMHP, de Maat MPM, Leebeek FWG, Kruip MJHA. Monitoring of treatment with vitamin K antagonists: recombinant thromboplastins are more sensitive to factor VII than tissue-extract thromboplastins. J Thromb Haemost 2017; 15:500-506. [PMID: 28055147 DOI: 10.1111/jth.13611] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Indexed: 11/29/2022]
Abstract
Essentials Differences in sensitivity to factor VII (FVII) have been suggested between thromboplastins. FVII-induced International Normalized Ratio (INR) changes differ between commercial reagents. Recombinant human thromboplastins are more sensitive to FVII than tissue-extract thromboplastins. Thromboplastin choice may affect FVII-mediated INR stability. SUMMARY Background Differences regarding sensitivity to factor VII have been suggested for recombinant human and tissue-extract thromboplastins used for International Normalized Ratio (INR) measurement, but the evidence is scarce. Differences in FVII sensitivity are clinically relevant, as they can affect INR stability during treatment with vitamin K antagonists (VKAs). Objectives To determine whether commercial thromboplastins react differently to changes in FVII. Methods We studied the effect of addition of FVII on the INR in plasma by using three tissue-extract (Neoplastin C1+, Hepato Quick, and Thromborel S) and three recombinant human (Recombiplastin 2G, Innovin, and CoaguChek XS) thromboplastins. Three different concentrations of purified human FVII (0.006, 0.012 and 0.062 μg mL-1 plasma), or buffer, were added to five certified pooled plasmas of patients using VKAs (INR of 1.5-3.5). Changes in FVII activity were measured with two bioassays (Neoplastin and Recombiplastin), and relative INR changes were compared between reagents. Results After addition of 0.062 μg mL-1 FVII, FVII activity in the pooled plasmas increased by approximately 20% (Neoplastin) or 32% (Recombiplastin) relative to the activity in pooled normal plasma. All thromboplastins showed dose-dependent INR decreases. The relative INR change in the pooled plasmas significantly differed between the six thromboplastins. No differences were observed among recombinant or tissue-extract thromboplastins. Pooled results indicated that the FVII-induced INR change was greater for recombinant than for tissue-extract thromboplastins. Conclusions Differences regarding FVII sensitivity exist between various thromboplastins used for VKA monitoring. Recombinant human thromboplastins are more sensitive to FVII than tissue-extract thromboplastins. Therefore, thromboplastin choice may affect FVII-mediated INR stability.
Collapse
Affiliation(s)
- J S Biedermann
- Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands
- Star-Medical Diagnostic Center, Rotterdam, the Netherlands
| | | | - M P M de Maat
- Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - F W G Leebeek
- Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - M J H A Kruip
- Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands
- Star-Medical Diagnostic Center, Rotterdam, the Netherlands
| |
Collapse
|
5
|
van den Besselaar AMHP, Witteveen E, van der Meer FJM. Long-term stability of frozen pooled plasmas stored at -70°C, -40°C, and -20°C for prothrombin time and International Normalized Ratio (INR) assessment. Thromb Res 2013; 131:349-51. [PMID: 23411127 DOI: 10.1016/j.thromres.2013.01.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2012] [Revised: 01/14/2013] [Accepted: 01/16/2013] [Indexed: 11/30/2022]
Abstract
BACKGROUND Frozen pooled plasmas may be used for quality assessment and local calibration of prothrombin time (PT) and International Normalized Ratio (INR) measurement systems. The purpose of the present study is to estimate the long-term stability of frozen pooled plasmas stored for at least three years. METHODS Six pooled plamas with different INR levels were stored at -70°C, -40°C, and -20°C for various time periods up to 1453days. PT of stored samples were measured with two thromboplastin reagents on a single automated coagulation instrument. INR was calculated from PT and plotted against plasma storage time. Linear regression lines of INR on storage time were used to estimate the percentage increase of INR. RESULTS INR of plasma stored at -40°C or -20°C increased significantly with time. INR of plasma stored at -70°C did not change significantly in 11 out of 12 cases. The INR change of pooled plasmas stored at -70°C for 3years varied between 0.07% and 2.03%. CONCLUSION Long-term storage of plasmas at -40°C or -20°C should be avoided. Pooled plasmas stored at -70°C can be used for quality assessment and local calibration for at least 3years.
Collapse
|
6
|
Use of INR calibrator plasmas in the routine coagulation laboratory: a study of two thrombolastin reagents. Thromb Res 2012; 130:e158-62. [PMID: 22682443 DOI: 10.1016/j.thromres.2012.05.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2012] [Revised: 04/29/2012] [Accepted: 05/11/2012] [Indexed: 11/22/2022]
Abstract
INR values may be either calculated with the ISI values supplied by thromboplastin manufacturers or are directly extrapolated from certified INR calibrator plasmas. We tested the principle of local INR calibration using INR calibrator plasmas (PT-Multi Calibrator, Siemens), two thromboplastin reagents (Neoplastin Plus, rabbit brain, Stago, coagulometer-specific ISI 1.31, and Innovin, recombinant human tissue factor, Siemens) and the same coagulometer (STA-R, Stago) in 100 patients on warfarin. Using a ISI value of 0.77 with Tomenson correction for Innovin (correction factor=1.09), INR values of patients were similar with the two reagents, with a bias of 0.03 INR units and no significant regression of the difference over the average INR by method comparison analysis. With the INR calibrator plasmas, INR values with Neoplastin Plus were lower than Innovin values with an average bias of 0.39 INR units and a significant regression of the difference over the average INR (r=-0.91). Significant bias (0.16 INR units, p<0.00001) and regression (r=-0.77) was also observed by comparison of Neoplastin Plus INRs with Innovin calibrated INRs. Based on a therapeutic INR interval of 2.0 to 3.5, discordance in warfarin dosing was approximately 3 times higher with INR calibration (27% vs 11%). Because of non commutability with fresh plasma samples, local INR calibration with lyophilized calibrator plasmas may not be valid for some reagent-instrument combinations.
Collapse
|
7
|
Remijn JA, Wildeboer B, van Suijlen JDE, Adriaansen HJ. Recombinant Thromboplastins vs Tissue-Extract Thromboplastins in Patients on Unstable Oral Anticoagulant Therapy. Clin Chem 2011; 57:916-7. [DOI: 10.1373/clinchem.2010.161364] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Jasper A Remijn
- Department of Clinical Chemistry and Laboratory Hematology Gelre ziekenhuizen Apeldoorn/Zutphen, the Netherlands
| | - Bertil Wildeboer
- Department of Clinical Chemistry and Laboratory Hematology Gelre ziekenhuizen Apeldoorn/Zutphen, the Netherlands
| | - Jeroen DE van Suijlen
- Department of Clinical Chemistry and Laboratory Hematology Gelre ziekenhuizen Apeldoorn/Zutphen, the Netherlands
| | - Henk J Adriaansen
- Department of Clinical Chemistry and Laboratory Hematology Gelre ziekenhuizen Apeldoorn/Zutphen, the Netherlands
| |
Collapse
|
8
|
Smith SA, Comp PC, Morrissey JH. Traces of factor VIIa modulate thromboplastin sensitivity to factors V, VII, X, and prothrombin. J Thromb Haemost 2006; 4:1553-8. [PMID: 16839353 DOI: 10.1111/j.1538-7836.2006.01971.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Thromboplastin reagents are used to conduct prothrombin time (PT) clotting tests to monitor oral anticoagulant therapy and screen for clotting factor deficiencies. Thromboplastins made from purified, recombinant tissue factor are generally more sensitive to changes in plasma factor (F) VII levels than are thromboplastins prepared from tissue extracts. This may be problematic as FVII's short plasma half-life can result in day-to-day fluctuation during oral anticoagulant therapy. We hypothesized that trace contamination of tissue-derived thromboplastins with FVII(a) blunts sensitivity to plasma FVII levels. METHODS Traces of purified FVIIa were added to thromboplastin reagents prepared using recombinant human tissue factor and the effect on sensitivity to individual clotting factors was quantified in PT clotting assays. RESULTS AND CONCLUSIONS Adding 5-100 pm FVIIa not only decreased thromboplastin sensitivity to plasma FVII, it surprisingly increased sensitivity to plasma levels of FV, FX and prothrombin. In addition, traces of FVIIa interacted with changes in the salt content and phospholipid composition of recombinant thromboplastins to further modulate their sensitivities to individual clotting factors. These results help explain how thromboplastin reagents of differing composition exhibit differing sensitivities to individual clotting factor levels. Implications of our results for monitoring oral anticoagulant therapy and other uses of the PT assay are discussed.
Collapse
Affiliation(s)
- S A Smith
- Department of Biochemistry, University of Illinois at Urbana-Champaign, 506 S. Mathews, Urbana, IL 61801, USA
| | | | | |
Collapse
|
9
|
Smith SA, Comp PC, Morrissey JH. Phospholipid composition controls thromboplastin sensitivity to individual clotting factors. J Thromb Haemost 2006; 4:820-7. [PMID: 16634752 DOI: 10.1111/j.1538-7836.2006.01848.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Tissue factor is the active ingredient in thromboplastin reagents used to perform prothrombin time (PT) clotting tests to monitor oral anticoagulant therapy and to screen for clotting factor deficiencies. Thromboplastins are complex mixtures prepared from extracts of brain or placenta, although newer thromboplastins contain recombinant tissue factor incorporated into phospholipid vesicles. Thromboplastins can vary widely in their sensitivity to reductions in the levels of vitamin K-dependent clotting factors. A system to compensate for this, the International Sensitivity Index (ISI) and International Normalized Ratio (INR), has revolutionized the monitoring of oral anticoagulant therapy. The INR system is also sometimes used to monitor coagulopathies in patients with sepsis or liver failure, applications for which it was not originally designed and for which it has not been rigorously validated. OBJECTIVES To better understand thromboplastin performance, we systematically investigated which properties of recombinant thromboplastins influence their sensitivities to changes in the levels of specific clotting factors. RESULTS We now report that relative sensitivities to changes in the plasma levels of factors V, VII, X (FV, FVII, FX) and prothrombin are differentially influenced by a recombinant thromboplastin's content of phospholipid and sodium chloride. Furthermore, thromboplastins of similar ISI values may exhibit quite different sensitivities to each of these clotting factors. CONCLUSIONS Differing sensitivities of thromboplastin reagents to individual clotting factor levels have implications for monitoring of oral anticoagulant therapy and interpreting results of the PT assay.
Collapse
Affiliation(s)
- S A Smith
- Department of Biochemistry, College of Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
| | | | | |
Collapse
|
10
|
Smith SA, Morrissey JH. Properties of recombinant human thromboplastin that determine the International Sensitivity Index (ISI). J Thromb Haemost 2004; 2:1610-6. [PMID: 15333038 DOI: 10.1111/j.1538-7836.2004.00897.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Prothrombin Time (PT) clotting tests are widely used to monitor oral anticoagulation therapy and to screen for clotting factor deficiencies. The active ingredient in PT reagents (thromboplastins) is tissue factor, the integral membrane protein that triggers the clotting cascade through the extrinsic pathway. Several years ago, a system for calibrating and using thromboplastin reagents, known as the International Sensitivity Index (ISI) and the International Normalized Ratio (INR), was developed to standardize monitoring of oral anticoagulant therapy. The ISI/INR method, while revolutionizing the monitoring of coumarin therapy, has been criticized for a number of perceived shortcomings. We have undertaken a series of studies aimed at achieving a detailed understanding of which parameters influence the ISI values of thromboplastin reagents, with an ultimate goal of creating 'designer thromboplastins' whose sensitivities to the various clotting factors can be individually tailored. In this study, we demonstrate that ISI values of thromboplastin reagents based on relipidated, recombinant human tissue factor can be controlled by a combination of changes in the phospholipid content (in particular, the levels of phosphatidylserine and phosphatidylethanolamine) and ionic strength. The sensitivity of a given thromboplastin reagent can be increased (i.e. its ISI value decreased) by decreasing the content of phosphatidylserine and/or increasing the ionic strength. The molar ratio of phospholipid to tissue factor, on the other hand, had essentially no impact on ISI value.
Collapse
Affiliation(s)
- S A Smith
- Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA
| | | |
Collapse
|
11
|
Houdijk WPM, Van Den Besselaar AMHP. International multicenter international sensitivity index (ISI) calibration of a new human tissue factor thromboplastin reagent derived from cultured human cells. J Thromb Haemost 2004; 2:266-70. [PMID: 14995988 DOI: 10.1111/j.1538-7836.2004.00434.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The international sensitivity index (ISI) of the first working standard of Simplastin HTF, a new human tissue factor thromboplastin derived from cultured human cells, has been assessed in a calibration exercise in two Canadian and five European laboratories. Calibrations against international reference preparations (IRP) were performed for the manual method and six types of automated coagulometers that cover the majority of clotting endpoint principles in routine use. The ISI was method-dependent and varied between 1.03 and 1.29 when calibrated against rTF/95 (human IRP). The ISI was also dependent on the route of calibration. Compared with calibration against rTF/95, the ISIs obtained by calibration against RBT/90 (rabbit IRP) were on average 4.4% higher (P < 0.005). Considering the principle of 'like vs. like', the ISIs obtained by calibration against rTF/95 should be preferred.
Collapse
|
12
|
Mischke R, Diedrich M, Nolte I. Sensitivity of different prothrombin time assays to factor VII deficiency in canine plasma. Vet J 2003; 166:79-85. [PMID: 12788020 DOI: 10.1016/s1090-0233(02)00250-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
The factor VII sensitivity of prothrombin time (PT) in dogs was tested using five different PT reagents and a commercial PT variant. The five PT reagents were used according to manufacturers' instructions (standard test, PT([ST])) and also using a modified test instruction (modified test, PT([MT])). Plasma samples with defined factor VII levels (10-100%) were prepared by adding increasing quantities of canine factor VII deficient plasma to the pooled plasma of healthy dogs. Statistical comparison based on prothrombin time ratios (PTR = PT sample: PT measured for 100% factor VII activity level) revealed significant differences between different reagents for PT([ST]) and also for PT([MT]). Factor VII activity at which PT was prolonged to the upper limit of the reference values (FVII([X(0.975)])) was 16-39% (PT([ST])) and 23-35% (PT([MT])). Factor VII sensitivity measured by PTR and also by FVII([X(0.975)]) values, was higher in four of five PT reagents using PT([MT]) when compared with PT([ST]). The results of this study indicate the importance of selecting a sensitive reagent and method for PT measurement and for careful interpretation of PT test results using canine plasma.
Collapse
Affiliation(s)
- R Mischke
- Clinic for Small Animals, School of Veterinary Medicine Hannover, Bischofsholer Damm 15, D-30173, Hannover, Germany.
| | | | | |
Collapse
|
13
|
Nishibe T, Parry G, Ishida A, Aziz S, Murray J, Patel Y, Rahman S, Strand K, Saito K, Saito Y, Hammond WP, Savidge GF, Mackman N, Wijelath ES. Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk-1/2 activation. Blood 2001; 97:692-9. [PMID: 11157486 DOI: 10.1182/blood.v97.3.692] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Tissue factor (TF), a transmembrane glycoprotein, initiates the extrinsic coagulation cascade. TF is known to play a major role in mediating thrombosis and thrombotic episodes associated with the progression of atherosclerosis. Macrophages at inflammatory sites, such as atherosclerotic lesions, release numerous cytokines that are capable of modulating TF expression. This study examined the role of oncostatin M (OSM), a macrophage/ T-lymphocyte-restricted cytokine, in the expression of TF in vascular smooth muscle cells (SMCs). It is reported here that OSM stimulated a biphasic and sustained pattern of TF messenger RNA (mRNA). The effect of OSM on TF mRNA expression was regulated at the transcriptional level as determined by nuclear run-offs and transient transfection of a TF promoter-reporter gene construct. OSM-induced TF expression was regulated primarily by the transcription factor NF-kappaB. Activation of NF-kappaB by OSM did not require IkappaB-alpha degradation. Inhibition of MEK activity by U0126 prevented OSM-induced TF expression by suppressing NF-kappaB DNA binding activity as determined by gel-shift analysis. Further, inhibition of Erk-1/2 protein by antisense treatment resulted in suppression of TF mRNA expression, indicating a role for Erk-1/2 in modulating NF-kappaB DNA binding activity. These studies suggest that the induced expression of TF by OSM is primarily through the activation of NF-kappaB and that activation of NF-kappaB is regulated in part by the MEK/Erk-1/2 signal transduction pathway. This study indicates that OSM may play a key role in promoting TF expression in SMCs within atherosclerotic lesions.
Collapse
Affiliation(s)
- T Nishibe
- Department of Molecular Biology, The Hope Heart Institute and Providence Medical Center, Seattle, WA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Bamford EJ, Bowen RH, Broad JP, Hawken A, Morgan J, Owen CL, Powell L, Sullivan BC, Tollick H, Wakeman L, Lewis MS, Beddall AC. A capillary whole blood method for measuring the INR. CLINICAL AND LABORATORY HAEMATOLOGY 2000; 22:279-85. [PMID: 11122269 DOI: 10.1046/j.1365-2257.2000.00331.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
This study describes a method of measuring the INR on native whole blood capillary samples using Innovin recombinant thromboplastin. Modification of the reagent was necessary to compensate for the nonoptimal level of calcium in the sample/reagent mixture. Ninety-five percent of results obtained by the capillary blood method were no more than 0.42 INR higher or 0.38 INR lower than the venous blood method. The effect of changes in haematocrit was minimal. Significant differences in results were found between the Innovin and Thrombotest capillary blood methods. Provided the reagent was properly stored, there was no reagent drift and satisfactory results were obtained on samples supplied by UKNEQAS (coagulation) from previous trials. The method described is a convenient, simple and accurate method of measuring the INR using native capillary whole blood and Innovin recombinant thromboplastin.
Collapse
Affiliation(s)
- E J Bamford
- Haematology Department, Neath General Hospital, Pant yr Heol, Neath, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|